ClinicalTrials.gg
Not yet recruitingNCT07278063DIABETEXX/3Updated Nov 9, 2026

Impact of Dietary Fat and Menstrual Cycle Phases in Type 1 Diabetes

An interventional study of Low Fat Mixed Meal and High Fat Mixed Meal in Type 1 Diabetes Mellitus, Glycemic Variability and Sex Characteristics, sponsored by Instituto de Investigacion Sanitaria La Fe. Not yet recruiting at 1 site in Spain. Open to participants aged 18 Years to 45 Years. Per ClinicalTrials.gov, last updated 2026-11-09.

Sponsored by Instituto de Investigacion Sanitaria La Fe · Not applicable, Interventional, and Treatment

How we know

Updated Nov 9, 2026Start date movedPrimary completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
50
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 150 studies in Diabetes Mellitus, Type 1 with a site in Spain — 25 open to participants now, 30 under way, 5 of them phase 3. Diabetes Mellitus, Type 1 · Spain.

Planned enrollment
80th of 113
50 · median 153
Started
2027
the only one that year
No phase
55 of 150
12 open now
Primary completion
2028-01
later than 20 of 29 live
Registered
139th of 150
by date

Among the 150 studies in Diabetes Mellitus, Type 1 with a site in Spain, this one is the 80th largest by planned enrollment of the 113 interventional ones that give a count, is the only one that started in 2027, is one of 55 with no phase, reaches primary completion later than 20 of the 29 other live ones, and was the 139th registered.

Diabetes Mellitus, Type 1

3,758 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.

Browse Diabetes Mellitus, Type 1 studies →

Open to participants now

25 of the 150 studies in Diabetes Mellitus, Type 1 with a site in Spain are open now. Recruiting first, the newest first:

19 more — sign in →

All 25 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 417 Diabetes Mellitus, Type 1 studies recruiting now, 130 (31%) set no upper age limit and 261 (63%) stop at 75 or younger; 187 take children under 18; 66 take healthy volunteers.

This study: 18 Years to 45 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 150 studies in Diabetes Mellitus, Type 1 with a site in Spain, or all of them as a file.
02

Study summary

This clinical trial aims to evaluate how variations in dietary fat content and hormonal status influence postprandial glycemic response in individuals with type 1 diabetes (T1D), with a special focus on women. The main objective is to clarify the impact of both factors individually and their interaction, which could inform more personalized strategies for insulin adjustment, optimizing glycemic control, and improving patient outcomes.

The main objective is to investigate the effects of low-fat versus high-fat meals, sex, menstrual cycle phases, and their interaction on postprandial glycemic control in adults with T1D treated with advanced hybrid closed-loop (AHCL) insulin delivery systems.

Specifically, the study will:

  • Compare postprandial glycemic responses after standardized low and high-fat meals in men and women with T1D.
  • Assess the differences in postprandial glycemic responses between early follicular and late luteal phases in women, using standardized meals with low and high fat content.
  • Identify sex-related differences in glycemic response after equivalent meals.

This research addresses the unmet clinical need for precise, tailored postprandial insulin dosing recommendations, especially among women whose insulin sensitivity fluctuates with menstrual phases. The results may contribute to sex-specific predictive models in AHCL systems, reducing acute complications and improving overall quality of life.

This is a randomized controlled crossover trial in which each participant serves as her/his own control. Fifty adults will be enrolled: 25 women and 25 men. Women will undergo four mixed-meal tests in random order:

  • low-fat given during the early follicular phase,
  • high-fat given during the early follicular phase,
  • low-fat given during the late luteal phase,
  • high-fat given during the late luteal phase. The menstrual phase will be confirmed with home-based hormonal monitoring devices that function with urine sample and use a single-use test wand (MIRA system).

Men will complete two mixed-meal tests (low-fat and high-fat), in randomized order.

All meals will be standardized for carbohydrate content and matched in other macronutrients, except for fat (with a 30-40g difference), administered after an 8-hour fast. The day of the mixed meal test, AHCL systems will be switched from automatic to manual mode just before eating to standardize the prandial insulin dose and to avoid differences in insulin infusion rates in the postprandial state due to algorithm compensations. Continuous glucose monitoring (CGM) and hourly capillary glucose testing will measure the postprandial response. Additional fasting blood samples will assess metabolic, hormonal, and lipid markers. Optional gastric emptying studies may be performed to exclude confounding gastroparesis in selected patients.

Participants will be recruited from the endocrinology outpatient unit of La Fe Polytechnic University Hospital . The projected recruitment period is from December 2025 to July 2027, with mixed-meal tests and data collection occurring between January 2026 and December 2027. Women are expected to complete the protocol in 6 weeks (4 tests), while men will require about 2 weeks (2 tests).

At baseline, participants will undergo blood tests to rule out endocrine disorders and confirm sex hormone status. Women participating in the study will use the MIRA home device to monitor their hormonal levels, allowing them to accurately determine and record the phases of their menstrual cycle as part of the study protocol. During meal tests, CGM (Freestyle Libre 3) will be used uniformly among subjects.

The study dependent variables will be the following:

  • Postprandial glucose area under the curve - AUC_PG_5h
  • Mean glucose level - MG
  • Continuous glucose monitoring metrics - TIR, TAR, TBR
  • Postprandial glucose standard deviation - SD
  • Postprandial glucose coefficient of variation - CV
  • Mean amplitude of glycemic excursions - MAGE
  • Mean of daily differences (MODD)

Independent variables are

  • Type of food: Meals with either low or high fat content.
  • Sex and Hormonal status: men; women during the early follicular phase; women during the late luteal phase.

If successful, this study will inform the development of more sophisticated, individualized insulin dosing algorithms and AHCL system improvements, especially for women with T1D. Results may lead to more effective management strategies, reduced GV, lower incidence of complications, and increased quality of life. Insights may directly support the personalization of diabetes care and improve gender equity in treatment standards.

Read the detailed description

Each female participant will initiate the protocol with the first mixed meal test during the luteal phase, using the MIRA home device to monitor their hormonal levels. This approach is intended to guarantee accurate assessment of menstruation, and assures the realization of the second mixed meal test in the subsequent follicular phase without interruption in all enrolled subjects..

The meaning of starting in the luteal phase is to avoid potential delays or absence of the menstrual cycle that could occur if randomization began in the follicular phase, which could render the planned sequence infeasible.

Randomization will be performed regarding the type of mixed meal administered: either high-fat or low-fat. Block randomization will be employed: 50% of participants commence with the low-fat meal, while the remaining 50% begin with the high-fat meal. This method is used to maintain balance between groups and to reduce allocation bias throughout the study.

The sample size calculation for this study was based on prior research evaluating postprandial glucose responses and the impact of menstrual cycle phases. Differences in glucose and glucose area under the curve (AUC) from mixed meals with varying fat content, as well as between menstrual phases, informed expected effect sizes. Assuming an intra-subject standard deviation of 25 mg/dl, a correlation of 0.5 between repeated measures, and an expected interaction effect of 20 mg/dl, a total of 50 participants (25 women and 25 men) is needed to achieve 80% statistical power with an alpha of 0.05. This ensures adequate power to detect meaningful differences in the postprandial glucose response measured by AUC according to meal fat content and menstrual cycle phase.

The study keeps the advanced hybrid closed-loop (AHCL) system active during the baseline period to maintain usual insulin delivery and ensure similar glucose concentrations just before the meal test and also during the previous hours. At the time of the mixed meal test, the system is switched to open-loop mode to standardize insulin dosing across all participants. This will prevent the pump from making automated insulin corrections to glucose excursions during the test, which would compensate, at least partially, the possible differences induced by the factors object of the investigation. The HCL systems will be maintained in the open-loop (manual) configuration from time 0 (prandial bolus administration) to the end of the study 5h after. The prandial insulin dose will be based on the usual individual insulin to carbohydrate ratio, while basal insulin will be infused at the planned safety mode rates (those rates programmed by the physician at which the systems infuse when it shift from the automatic to the manual mode). Importantly, both parameters (insulin to carbohydrate ratio and manual basal rates) will be optimized for each patient before the commencement of the meal tests and kept constant during the study participation.

This approach will help ensure similar preprandial glycemia between subjects, avoids confounding factors introduced by adaptive insulin delivery and will allow accurate assessment of the effects of meal composition and hormonal status on postprandial glucose response. Maintaining insulin dosing standardization is essential to isolate the variables under study without interference from the AHCL system's automatic glucose adjustments.

03

Conditions studied

  • Type 1 Diabetes Mellitus
  • Glycemic Variability
  • Sex Characteristics
  • Menstrual Cycle
  • Dietary Fat
  • Postprandial Glucose

Keywords

  • Type 1 diabetes
  • glycemic variability
  • advanced hybrid closed-loop systems
  • menstrual cycle
  • postprandial glucose
  • dietary fat
  • insulin sensitivity
  • continuous glucose monitoring
  • mixed-meal test
  • personalized insulin therapy
04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with a confirmed diagnosis of type 1 diabetes mellitus for more than 2 years, in treatment with AHCL (Advanced Hybrid Closed Loop) system treatment for at least 6 months.
  • Both sexes.
  • Metabolic control with \<8%.
  • between 18.5 and 29.99 (normal weight to overweight).
  • For women: regular menstrual cycles (21-35 days in length with variation between cycles of \<4 days) and no use of hormonal treatment.

Exclusion criteria

Exclusion Criteria:

  • Diagnosis of diabetic gastroparesis.
  • Presence of hypogonadism, anovulation, hyperandrogenism, hyperprolactinemia, pregnancy, or decompensated chronic diseases.
  • Use of oral medications that alter glucose metabolism.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Single (Outcomes assessor)
Enrollment
50 participants (estimated)

Study arms

  • Other
    Female1

    Female patients in early follicular phase

    Other: Low Fat Mixed Meal · Other: High Fat Mixed Meal

  • Other
    Female2

    Female patients in late luteal phase

    Other: Low Fat Mixed Meal · Other: High Fat Mixed Meal

  • Other
    Male

    Male patients

    Other: Low Fat Mixed Meal · Other: High Fat Mixed Meal

Interventions

  • OtherLow Fat Mixed Meal

    The patients will eat a standardized meal designed to evaluate how their blood glucose responds to food intake under controlled conditions. This meal contains a balanced proportion of carbohydrates, proteins, and a low fat content.

  • OtherHigh Fat Mixed Meal

    The patients will eat a standardized meal designed to evaluate how their blood glucose responds to food intake under controlled conditions. This meal contains a balanced proportion of carbohydrates, proteins, and a high fat content.

06

What researchers measure

Primary outcomes

  1. Postprandial glucose area under the curve (AUC_PG_5h)

    Postprandial glucose effect of the interaction between fat intake and hormonal condition. Difference in the area under de curve during 5 hour period as a function of the fat content of the meal and the hormonal condition, expressed in mg·h/dL: Post prandial AUC\_PG\_5h in female subjects, follicular phase, low fat: FFL\_AUC\_PG\_5h Post prandial AUC\_PG\_5h in female subjects, follicular phase, high fat: FFH\_AUC\_PG\_5h Post prandial AUC\_PG\_5h in female subjects, luteal phase, low fat: FLL\_AUC\_PG\_5h Post prandial AUC\_PG\_5h in female subjects, luteal phase, high fat: FLH\_AUC\_PG\_5h Post prandial AUC\_PG\_5h in male subjects, low fat: ML\_AUC\_PG\_5h Post prandial AUC\_PG\_5h in male subjects, high fat: MH\_AUC\_PG\_5h

    Time frame: 5 hours after each mixed-meal test.

Secondary outcomes

  1. Mean glucose level (MG)

    Derived from CGM data, expressed in milligrams per deciliter (mg/dL).

    Time frame: 5 hours after mixed-meal test.

  2. Time in range (TIR)

    Derived from CGM data. Expressed as a percentage (%) of the time or readings with glucose values within the target range, typically between 70-180 mg/dL

    Time frame: 5 hours after mixed-meal test

  3. Time above range (TAR)

    Derived from CGM data. Expressed as a percentage (%) of the time or readings when glucose exceeds 180 mg/dL

    Time frame: 5 hours after mixed-meal test

  4. Time below range (TBR)

    Derived from CGM data. Expressed as a percentage (%) of the time or readings when glucose falls below 70 mg/dL

    Time frame: 5 hours after mixed-meal test

  5. Postprandial glucose standard deviation (SD)

    Derived from CGM data, expressed in milligrams per deciliter (mg/dL)

    Time frame: 5 hours after mixed-meal test.

  6. Glycemic coefficient of variation (CV)

    Derived from CGM data, expressed as a percentage (%), calculated as (SD / mean glucose) × 100

    Time frame: 5 hours after mixed-meal test

  7. Mean amplitude of glycemic excursions (MAGE)

    Derived from CGM data, expressed in milligrams per deciliter (mg/dL)

    Time frame: 5 hours post each mixed-meal

  8. Mean of daily differences (MODD)

    Calculated from CGM data as the average of absolute differences between glucose values at the same time on consecutive days, expressed in milligrams per deciliter (mg/dL).

    Time frame: 24-hour continuous glucose monitoring period before and after the mixed meal

07

Study locations

1 site
08

References and documents

Publications

  • Monroy G, Picon-Cesar MJ, Garcia-Aleman J, Tinahones FJ, Martinez-Montoro JI. Glycemic Control Across the Menstrual Cycle in Women with Type 1 Diabetes Using the MiniMed 780G Advanced Hybrid Closed-Loop System: The 780MENS Prospective Study. Diabetes Technol Ther. 2025 May;27(5):395-401. doi: 10.1089/dia.2024.0522. Epub 2025 Jan 16. PubMed 39898554 ↗
  • Mesa A, Sola C, Vinagre I, Roca D, Granados M, Pueyo I, Cabre C, Conget I, Gimenez M. Impact of an Advanced Hybrid Closed-Loop System on Glycemic Control Throughout the Menstrual Cycle in Women with Type 1 Diabetes Prone to Hypoglycemia. Diabetes Technol Ther. 2024 Sep;26(9):667-672. doi: 10.1089/dia.2023.0571. Epub 2024 May 10. PubMed 38441905 ↗
  • Levy CJ, O'Malley G, Raghinaru D, Kudva YC, Laffel LM, Pinsker JE, Lum JW, Brown SA; iDCL Trial Research Group. Insulin Delivery and Glucose Variability Throughout the Menstrual Cycle on Closed Loop Control for Women with Type 1 Diabetes. Diabetes Technol Ther. 2022 May;24(5):357-361. doi: 10.1089/dia.2021.0431. Epub 2022 Feb 21. PubMed 35099294 ↗
  • Trout KK, Rickels MR, Schutta MH, Petrova M, Freeman EW, Tkacs NC, Teff KL. Menstrual cycle effects on insulin sensitivity in women with type 1 diabetes: a pilot study. Diabetes Technol Ther. 2007 Apr;9(2):176-82. doi: 10.1089/dia.2006.0004. PubMed 17425444 ↗
  • Tatulashvili S, Baptiste Julla J, Sritharan N, Rezgani I, Levy V, Bihan H, Riveline JP, Cosson E. Ambulatory Glucose Profile According to Different Phases of the Menstrual Cycle in Women Living With Type 1 Diabetes. J Clin Endocrinol Metab. 2022 Sep 28;107(10):2793-2800. doi: 10.1210/clinem/dgac443. PubMed 35869507 ↗
  • Brown SA, Jiang B, McElwee-Malloy M, Wakeman C, Breton MD. Fluctuations of Hyperglycemia and Insulin Sensitivity Are Linked to Menstrual Cycle Phases in Women With T1D. J Diabetes Sci Technol. 2015 Oct 14;9(6):1192-9. doi: 10.1177/1932296815608400. PubMed 26468135 ↗
  • Herranz L, Saez-de-Ibarra L, Hillman N, Gaspar R, Pallardo LF. [Glycemic changes during menstrual cycles in women with type 1 diabetes]. Med Clin (Barc). 2016 Apr 1;146(7):287-91. doi: 10.1016/j.medcli.2015.11.044. Epub 2016 Feb 18. Spanish. PubMed 26897501 ↗
  • Barata DS, Adan LF, Netto EM, Ramalho AC. The effect of the menstrual cycle on glucose control in women with type 1 diabetes evaluated using a continuous glucose monitoring system. Diabetes Care. 2013 May;36(5):e70. doi: 10.2337/dc12-2248. No abstract available. PubMed 23613610 ↗
  • Goldner WS, Kraus VL, Sivitz WI, Hunter SK, Dillon JS. Cyclic changes in glycemia assessed by continuous glucose monitoring system during multiple complete menstrual cycles in women with type 1 diabetes. Diabetes Technol Ther. 2004 Aug;6(4):473-80. doi: 10.1089/1520915041705875. PubMed 15321002 ↗
  • Gamarra E, Trimboli P. Menstrual Cycle, Glucose Control and Insulin Sensitivity in Type 1 Diabetes: A Systematic Review. J Pers Med. 2023 Feb 20;13(2):374. doi: 10.3390/jpm13020374. PubMed 36836608 ↗
  • Concepcion Zavaleta MJ, Gonzales Yovera JG, Moreno Marreros DM, Rafael Robles LDP, Palomino Taype KR, Soto Galvez KN, Arriola Torres LF, Coronado Arroyo JC, Concepcion Urteaga LA. Diabetic gastroenteropathy: An underdiagnosed complication. World J Diabetes. 2021 Jun 15;12(6):794-809. doi: 10.4239/wjd.v12.i6.794. PubMed 34168729 ↗
  • Horowitz M, O'Donovan D, Jones KL, Feinle C, Rayner CK, Samsom M. Gastric emptying in diabetes: clinical significance and treatment. Diabet Med. 2002 Mar;19(3):177-94. doi: 10.1046/j.1464-5491.2002.00658.x. PubMed 11918620 ↗
  • Aigner L, Becker B, Gerken S, Quast DR, Meier JJ, Nauck MA. Day-to-Day Variations in Fasting Plasma Glucose Do Not Influence Gastric Emptying in Subjects With Type 1 Diabetes. Diabetes Care. 2021 Feb;44(2):479-488. doi: 10.2337/dc20-1660. Epub 2020 Dec 7. PubMed 33288653 ↗
  • Mashali G, Kaul A, Khoury J, Corsiglia J, Dolan LM, Shah AS. Screening for Gastric Sensory Motor Abnormalities in Pediatric Patients With Type 1 Diabetes. Endocr Pract. 2023 Mar;29(3):168-173. doi: 10.1016/j.eprac.2022.12.014. Epub 2022 Dec 23. PubMed 36572278 ↗
  • Bartholome R, Salden B, Vrolijk MF, Troost FJ, Masclee A, Bast A, Haenen GR. Paracetamol as a Post Prandial Marker for Gastric Emptying, A Food-Drug Interaction on Absorption. PLoS One. 2015 Sep 9;10(9):e0136618. doi: 10.1371/journal.pone.0136618. eCollection 2015. PubMed 26352940 ↗
  • Cai Y, Li M, Zhang L, Zhang J, Su H. The effect of the modified fat-protein unit algorithm compared with that of carbohydrate counting on postprandial glucose in adults with type-1 diabetes when consuming meals with differing macronutrient compositions: a randomized crossover trial. Nutr Metab (Lond). 2023 Oct 16;20(1):43. doi: 10.1186/s12986-023-00757-w. PubMed 37845717 ↗
  • Smith TA, Smart CE, Fuery MEJ, Howley PP, Knight BA, Harris M, King BR. In children and young people with type 1 diabetes using Pump therapy, an additional 40% of the insulin dose for a high-fat, high-protein breakfast improves postprandial glycaemic excursions: A cross-over trial. Diabet Med. 2021 Jul;38(7):e14511. doi: 10.1111/dme.14511. Epub 2021 Feb 3. PubMed 33405297 ↗
  • Gillingham MB, Marak MC, Riddell MC, Calhoun P, Gal RL, Patton SR, Jacobs PG, Castle JR, Clements MA, Doyle FJ, Rickels MR, Martin CK. The Association Between Diet Quality and Glycemic Outcomes Among People with Type 1 Diabetes. Curr Dev Nutr. 2024 Mar 26;8(4):102146. doi: 10.1016/j.cdnut.2024.102146. eCollection 2024 Apr. PubMed 38638557 ↗
  • Colasanto A, Savastio S, Pozzi E, Gorla C, Coisson JD, Arlorio M, Rabbone I. The Impact of Different Types of Rice and Cooking on Postprandial Glycemic Trends in Children with Type 1 Diabetes with or without Celiac Disease. Nutrients. 2023 Mar 29;15(7):1654. doi: 10.3390/nu15071654. PubMed 37049494 ↗
  • Lodefalk M, Aman J, Bang P. Effects of fat supplementation on glycaemic response and gastric emptying in adolescents with Type 1 diabetes. Diabet Med. 2008 Sep;25(9):1030-5. doi: 10.1111/j.1464-5491.2008.02530.x. PubMed 19183308 ↗
  • Abdou M, Hafez MH, Anwar GM, Fahmy WA, Abd Alfattah NM, Salem RI, Arafa N. Effect of high protein and fat diet on postprandial blood glucose levels in children and adolescents with type 1 diabetes in Cairo, Egypt. Diabetes Metab Syndr. 2021 Jan-Feb;15(1):7-12. doi: 10.1016/j.dsx.2020.11.020. Epub 2020 Nov 26. PubMed 33276255 ↗
  • Wolpert HA, Atakov-Castillo A, Smith SA, Steil GM. Dietary fat acutely increases glucose concentrations and insulin requirements in patients with type 1 diabetes: implications for carbohydrate-based bolus dose calculation and intensive diabetes management. Diabetes Care. 2013 Apr;36(4):810-6. doi: 10.2337/dc12-0092. Epub 2012 Nov 27. PubMed 23193216 ↗
  • Garonzi C, Forsander G, Maffeis C. Impact of Fat Intake on Blood Glucose Control and Cardiovascular Risk Factors in Children and Adolescents with Type 1 Diabetes. Nutrients. 2021 Jul 29;13(8):2625. doi: 10.3390/nu13082625. PubMed 34444784 ↗
  • Bell KJ, Fio CZ, Twigg S, Duke SA, Fulcher G, Alexander K, McGill M, Wong J, Brand-Miller J, Steil GM. Amount and Type of Dietary Fat, Postprandial Glycemia, and Insulin Requirements in Type 1 Diabetes: A Randomized Within-Subject Trial. Diabetes Care. 2020 Jan;43(1):59-66. doi: 10.2337/dc19-0687. Epub 2019 Aug 27. PubMed 31455688 ↗
  • Garcia A, Moscardo V, Ramos-Prol A, Diaz J, Boronat M, Bondia J, Rossetti P. Effect of meal composition and alcohol consumption on postprandial glucose concentration in subjects with type 1 diabetes: a randomized crossover trial. BMJ Open Diabetes Res Care. 2021 Oct;9(1):e002399. doi: 10.1136/bmjdrc-2021-002399. PubMed 34620620 ↗
  • de Wit DF, Fuhri Snethlage CM, Rampanelli E, Maasen K, Walpot N, van Raalte DH, Nieuwdorp M, Soeters MR, Hanssen NMJ. Higher fibre and lower carbohydrate intake are associated with favourable CGM metrics in a cross-sectional cohort of 470 individuals with type 1 diabetes. Diabetologia. 2024 Oct;67(10):2199-2209. doi: 10.1007/s00125-024-06213-5. Epub 2024 Jul 5. PubMed 38967668 ↗
  • Lupoli R, Pisano F, Capaldo B. Postprandial Glucose Control in Type 1 Diabetes: Importance of the Gastric Emptying Rate. Nutrients. 2019 Jul 10;11(7):1559. doi: 10.3390/nu11071559. PubMed 31295897 ↗
  • Vetrani C, Calabrese I, Cavagnuolo L, Pacella D, Napolano E, Di Rienzo S, Riccardi G, Rivellese AA, Annuzzi G, Bozzetto L. Dietary determinants of postprandial blood glucose control in adults with type 1 diabetes on a hybrid closed-loop system. Diabetologia. 2022 Jan;65(1):79-87. doi: 10.1007/s00125-021-05587-0. Epub 2021 Oct 23. PubMed 34689215 ↗
  • Zeevi D, Korem T, Zmora N, Israeli D, Rothschild D, Weinberger A, Ben-Yacov O, Lador D, Avnit-Sagi T, Lotan-Pompan M, Suez J, Mahdi JA, Matot E, Malka G, Kosower N, Rein M, Zilberman-Schapira G, Dohnalova L, Pevsner-Fischer M, Bikovsky R, Halpern Z, Elinav E, Segal E. Personalized Nutrition by Prediction of Glycemic Responses. Cell. 2015 Nov 19;163(5):1079-1094. doi: 10.1016/j.cell.2015.11.001. PubMed 26590418 ↗

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jan 2027; primary completion for Jan 2028, 12 months later.

Of 852 non-industry interventional studies with no phase under Diabetes Mellitus, Type 1, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 37. This study's planned 12 months is below that.

Counting every sponsor, half of 957 studies reached it within 18 months; a quarter within 9 and three quarters within 35.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 9, 2026: start May 2026 → Jan 2027, primary completion Oct 2027 → Jan 2028 and completion Apr 2028 → Jul 2028.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Nov 29, 2025
First posted
Dec 11, 2025
StartEst.
Jan 2027was May 2026
Primary completionEst.
Jan 2028was Oct 2027
CompletionEst.
Jul 2028was Apr 2028
Last update
Nov 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
May 2026→Jan 2027
Nov 9, 2026
Primary completion
Oct 2027→Jan 2028
Nov 9, 2026
Study completion
Apr 2028→Jul 2028
Nov 9, 2026
Show all 1 update
  1. Nov 9, 2026
    Start date May 2026→Jan 2027
    Primary completion Oct 2027→Jan 2028
    Study completion Apr 2028→Jul 2028
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07278063
Lead sponsor
Instituto de Investigacion Sanitaria La Fe
Collaborators
Universitat Politècnica de València, Hospital Universitario La Fe
Responsible party
Paolo Rossetti (Clinical Researcher, Instituto de Investigacion Sanitaria La Fe) — Principal investigator
First posted
Dec 11, 2025
Start date
Jan 2027 (estimated)
Primary completion
Jan 2028 (estimated)
Completion
Jul 2028 (estimated)
Last update
Nov 9, 2026

Study contacts

Paolo Rossetti, Medicine
Contact
rossetti_paolo@gva.es
+34608109913
Olga Segui, Medicine
Contact
oseguicot@gmail.com
+34680705127

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion